Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...

Parnassus Core Equity Fund sees Eli Lilly And Co. (NYSE:LLY) as a strong long-term investment due to its GLP-1 franchise and ...

Eli Lilly (LLY) has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug ...

Eli Lilly's weekly prescription data for Zepbound is up 354% year over year while Novo Nordisk's Wegovy is up just 61%.

Eli Lilly's stock dropped over 7% after announcing a lowered profit forecast, despite exceeding Q1 expectations.

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...

Eli Lilly (LLY) stock dips despite strong weight-loss drug sales as the company's Q1 2025 results fall short of forecasts.

Short interest in Eli Lilly and Co (NYSE:LLY) decreased during the last reporting period, falling from 7.02M to 6.43M. This put 0.81% of the company's publicly available shares short. Short ...

From a fundamental standpoint, Eli Lilly presently has a market capitalization of $789 billion. Over the trailing twelve ...

Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...